Welcome to our dedicated page for Generation Bio news (Ticker: GBIO), a resource for investors and traders seeking the latest updates and insights on Generation Bio stock.
Generation Bio Co. has reported biotechnology and corporate-status developments tied to its historical focus on genetic-medicine approaches for T cell-driven autoimmune diseases. Company updates have covered the ctLNP cell-targeted lipid nanoparticle delivery system, siRNA delivery to T cells, operating and financial results, stock and listing-related actions, equity awards, and leadership transitions.
Later public disclosures also place GBIO in a corporate transition context, with strategic-alternatives language followed by regulatory records addressing delisting and Exchange Act deregistration notices for its common stock.
Generation Bio Co (Nasdaq: GBIO) reported promising preclinical data at the ESGCT Annual Virtual Congress, showcasing the efficacy of their cell-targeted lipid nanoparticle (ctLNP) delivery platform for retinal therapies. The data indicated broad delivery and durable expression of closed-ended DNA (ceDNA) comparable to AAV5, suggesting potential for gene editing in retinal diseases. Financially, they reported a net loss of $31.9 million for Q3 2021, an increase from $20.8 million in Q3 2020, with R&D expenses rising to $22 million. Cash reserves improved to $398.4 million as of September 30, 2021.
Generation Bio Co (Nasdaq: GBIO) presented new preclinical data at the ESGCT 2021 Annual Virtual Congress, demonstrating effective sub-retinal delivery of closed-ended DNA (ceDNA) using its cell-targeted lipid nanoparticle (ctLNP). The study shows broad photoreceptor distribution and durable expression with ctLNP in rodents, comparable to AAV5. Additionally, ctLNP mRNA delivery in non-human primates indicates potential as a leading non-viral method for gene editing in the retina. This platform aims to address inherited retinal diseases and expand opportunities for gene therapy.
Generation Bio Co. (Nasdaq: GBIO), a leader in genetic medicines for rare and prevalent diseases, announced that its CEO, Geoff McDonough, will participate in a fireside chat at the Jefferies Virtual Gene Therapy/Editing Summit on October 27 at 5:00 p.m. ET. A live webcast will be available on the company's investor website, with a replay accessible for 30 days after the event. The company focuses on innovative genetic therapies through its proprietary non-viral platform, which aims to provide durable treatments and scalable manufacturing for more patients globally.
On October 15, 2021, Generation Bio (Nasdaq: GBIO) announced an upcoming oral presentation at the European Society of Gene and Cell Therapy Annual Virtual Congress, scheduled for October 19-22. The presentation will showcase preclinical advancements in retinal therapies using a novel lipid nanoparticle for broad cellular delivery. Matthew Stanton, Ph.D., emphasized the potential of their non-viral delivery system to address challenges faced by viral gene therapies. Attendees can access the presentation online on October 22 and a recorded version for 30 days afterward.
Generation Bio (Nasdaq: GBIO) reported its second-quarter 2021 financial results, showcasing a cash position of $425.2 million as of June 30, 2021, a notable increase from $262.3 million at the end of 2020. R&D expenses rose to $22.7 million, up from $13.5 million year-over-year. The net loss expanded to $30.8 million, or $0.55 per share, compared to a net loss of $17.7 million or $1.50 per share last year. The company is transitioning to a new manufacturing process and has signed a lease for a 104,000 square feet cGMP facility in Waltham, expected to be operational in 2023.
Generation Bio Co. (Nasdaq: GBIO) announces participation of CEO Geoff McDonough, M.D., in a panel discussion at the Wedbush PacGrow Healthcare Conference 2021 on August 10 at 9:10 a.m. ET. The event will focus on the company's innovations in genetic medicines for rare and prevalent diseases. A live webcast will be available on the company's investor website, with a replay accessible for 30 days post-event. Generation Bio's unique platform, utilizing closed-ended DNA and advanced lipid nanoparticle delivery, aims to provide durable treatments and scalable manufacturing for genetic therapies.
Generation Bio (Nasdaq: GBIO) announced a transition to rapid enzymatic synthesis (RES) for its closed-ended DNA manufacturing across all programs, enhancing quality, scale, and speed. A lease agreement was signed for a cGMP manufacturing facility in Waltham, MA, expected to be operational in 2023. The company anticipates submitting an IND application for hemophilia A by year-end 2023, with factor VIII expression data anticipated in late 2021. Despite incurring $104 million in lease costs and $45 million in facility investments, the company expects its cash runway to remain sufficient until 2024.
Generation Bio, a leader in genetic medicines, announced that CEO Geoff McDonough will present at the William Blair Biotech Focus Conference on July 15, 2021, at 9:00 a.m. ET. The event will feature a live webcast available on their investor website, with a replay accessible for 30 days. Generation Bio focuses on developing non-viral gene therapies aimed at providing durable treatments for various diseases. Their innovative platform utilizes closed-ended DNA and a specialized delivery system to target specific tissues for effective therapy.
Generation Bio Co. (Nasdaq: GBIO) announced that CEO Geoff McDonough will present at the JMP Securities Life Sciences Conference on June 16 at 11:30 a.m. ET. A live webcast of the presentation will be available on the company's investor website, with a replay available for 30 days. The company specializes in non-viral gene therapies aimed at providing durable treatments for various diseases, utilizing a unique platform that combines high-capacity DNA constructs and targeted delivery systems. Generation Bio is committed to broadening access to gene therapy worldwide.
Generation Bio Co. (Nasdaq: GBIO) has announced that its CEO, Geoff McDonough, will be presenting at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 11:30 a.m. ET. The presentation will be accessible via a live webcast on the company’s investor website, with a replay available for 30 days after.
Generation Bio specializes in non-viral gene therapies aimed at providing durable treatments for various diseases. Their innovative platform employs closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle system to enhance gene delivery and efficacy.